Safety and Anti-Tumor Activity of TYRA-200 in Advanced Cholangiocarcinoma With Activating FGFR2 Gene Alterations
Conditions: Locally Advanced Cholangiocarcinoma; Intrahepatic Cholangiocarcinoma; Solid Tumor; Metastatic Cholangiocarcinoma Interventions: Drug: Phase 1 Part A - dose escalation TYRA-200 taken once daily by mouth in 28-day cycles; Drug: Phase 1 Part B - dose expansion TYRA-200 taken once daily by mouth in 28-day cycles Sponsors: Tyra Biosciences, Inc Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 7, 2023 Category: Research Source Type: clinical trials
Precision Medicine for Combined Hepatocellular-Cholangiocarcinoma
Conditions: Liver Cancer Interventions: Other: phenotyping Sponsors: Inserm U955 Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 24, 2023 Category: Research Source Type: clinical trials
Liver Transplantation in Intrahepatic Cholangiocarcinoma
Conditions: Locally Advanced Non-metastatic Intrahepatic Cholangiocarcinoma; Determine Efficacy of Liver Transplantation After Neoadjuvant Systemic Therapy in Patients With Locally Advanced Non-metastatic Intrahepatic Cholangiocarcinoma Interventions: Procedure: Liver Transplant Sponsors: Rutgers, The State University of New Jersey Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 18, 2023 Category: Research Source Type: clinical trials
Combination Therapy of HAIC, Surufatinib and Tislelizumab for Unresectable or Metastatic Biliary Tract Cancer
Conditions: Carcinoma; Intrahepatic Cholangiocarcinoma; Gallbladder Cancer; Surufatinib; Angiogenesis Inhibitors; Tislelizumab; Antineoplastic Agents, Immunological; Immunotherapy Interventions: Drug: HAIC; Drug: Surufatinib; Drug: Tislelizumab Sponsors: Wuhan Union Hospital, China Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 16, 2023 Category: Research Source Type: clinical trials
Tripegfilgrastim Trial to Reduce the Risk of Severe Neutropenia in Patients With Unresectable Pancreaticobiliary Cancers
Conditions: Unresectable Pancreatic Cancer; Unresectable Bile Duct Carcinoma; Unresectable Biliary Tract Carcinoma Interventions: Drug: Tripegfilgrastim Sponsors: National Cancer Center, Korea; Seoul National University Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 16, 2023 Category: Research Source Type: clinical trials
Clinical Study of CEA Targeting Chimeric Antigen Receptor T Lymphocytes （CAR-T） for CEA Positive Advanced Malignant Solid Tumors
Conditions: Gastric Cancer; Colon Cancer; Rectal Cancer; Breast Cancer; Lung Cancer; Esophagus Cancer; Cholangiocarcinoma; Pancreas Cancer Interventions: Biological: CEA-targeted CAR-T cells; Biological: CEA-targeted CAR-T cells Sponsors: Chongqing Precision Biotech Co., Ltd; First Affiliated Hospital of Wannan Medical College Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 10, 2023 Category: Research Source Type: clinical trials
LIver TrAnspLantation for Non-resectable Peri-HIlar cholangioCArcinoma (LITALHICA)
Conditions: Perihilar Cholangiocarcinoma Interventions: Procedure: Liver transplantation Sponsors: Azienda Sanitaria Ospedaliera; Istituto Oncologico Veneto IRCCS Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 9, 2023 Category: Research Source Type: clinical trials
Endoscopic Scissors Cutting Nasobiliary Duct VS Bilateral Plastic Stent
Conditions: Cholangiocarcinoma, Hilar; Biliary Stricture; Hilar Cholangiocarcinoma; Klatskin Tumor; Biliary Disease; Bile Duct Diseases; Bile Duct Stenosis Interventions: Device: Endoscopic nasobiliary duct cutting; Device: Bilateral plastic stent Sponsors: First People ' s Hospital of Hangzhou Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 30, 2023 Category: Research Source Type: clinical trials
Locally ablatIVe thErapy for oLigo-progressive gastrOintestiNal maliGnancies (LIVELONG)
Conditions: Esophageal Cancer; Small Bowel Cancer; Gastroesophageal-junction Cancer; Gastric Cancer; Colorectal Cancer; Appendiceal Cancer; Biliary Cancer; Gall Bladder Cancer; Intrahepatic Cholangiocarcinoma; Extrahepatic Cholangiocarcinoma; Oligoprogressive Interventions: Device: Ablative local therapy Sponsors: University of California, Davis; National Cancer Institute (NCI) Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 26, 2023 Category: Research Source Type: clinical trials
LIver Transplantation for Non-Resectable Intrahepatic CholAngiocarcinoma
Conditions: Intrahepatic Cholangiocarcinoma Interventions: Procedure: Liver transplantation Sponsors: Azienda Sanitaria Ospedaliera Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 24, 2023 Category: Research Source Type: clinical trials
A Study to Evaluate the Safety and Efficacy of PRRT With 177Lu-EB-FAPI in Patients With Advanced Cholopancreatic Tumors
Conditions: Advanced Pancreatic Cancer and Cholangiocarcinoma Interventions: Drug: PRRT with 177Lu-EB-FAPI Sponsors: Zhejiang University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 13, 2023 Category: Research Source Type: clinical trials
A Phase 2 Study of Ivosidenib in Previously Treated Japanese Subjects With Nonresectable or Metastatic Cholangiocarcinoma With an IDH1 Mutation
Conditions: Cholangiocarcinoma Non-resectable; Cholangiocarcinoma Metastatic Interventions: Drug: Ivosidenib Sponsors: Servier Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 13, 2023 Category: Research Source Type: clinical trials
Modified vs Conventional Blumgart Anastomosis of LPD for the Effects of Pancreatic Fistula of Periampullary Carcinoma
Conditions: Ampullary Cancer; Bile Duct Cancer; Pancreas Cancer; Duodenum Cancer Interventions: Procedure: Modified Blumgart Anastomosis in LPD; Procedure: conventional Blumgart anastomosis in LPD Sponsors: Affiliated Hospital of Guangdong Medical University Enrolling by invitation (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 10, 2023 Category: Research Source Type: clinical trials
Radioembolization With Tremelimumab and Durvalumab for Locally Advanced, Unresectable Intrahepatic Cholangiocarcinoma
Conditions: Locally Advanced Intrahepatic Cholangiocarcinoma; Oligometastatic Intrahepatic Cholangiocarcinoma; Stage III Intrahepatic Cholangiocarcinoma AJCC v8; Stage IV Intrahepatic Cholangiocarcinoma AJCC v8; Unresectable Intrahepatic Cholangiocarcinoma Interventions: Procedure: Angiography; Procedure: Biopsy; Procedure: Biospecimen Collection; Procedure: Computed Tomography; Biological: Durvalumab; Procedure: Magnetic Resonance Imaging; Procedure: Positron Emission Tomography; Biological: Tremelimumab; Procedure: Yttrium -90 Microsphere Radioembol...
Source: ClinicalTrials.gov - September 28, 2023 Category: Research Source Type: clinical trials
Radioembolization With Tremelimumab and Durvalumab for Locally Advanced, Unresectable Intrahepatic Cholangiocarcinoma
Conditions: Locally Advanced Intrahepatic Cholangiocarcinoma; Oligometastatic Intrahepatic Cholangiocarcinoma; Stage III Intrahepatic Cholangiocarcinoma AJCC v8; Stage IV Intrahepatic Cholangiocarcinoma AJCC v8; Unresectable Intrahepatic Cholangiocarcinoma Interventions: Procedure: Angiography; Procedure: Biopsy; Procedure: Biospecimen Collection; Procedure: Computed Tomography; Biological: Durvalumab; Procedure: Magnetic Resonance Imaging; Procedure: Positron Emission Tomography; Biological: Tremelimumab; Procedure: Yttrium-90 Microsphere Radioembolization Sponsors: Mayo Clinic; National Cancer Institute (NCI) Not yet rec...
Source: ClinicalTrials.gov - September 28, 2023 Category: Research Source Type: clinical trials
